Benzinga | Jun 3, 2021 10:02AM EDT

Zynerba Pharmaceuticals Announces Presentation Of Efficacy, Safety Findings In Children, Adolescents With Autism Spectrum Disorder (ASD) And Related Disorders At 2021 American Society Of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00 a.m. -- 11:00 a.m. ET in poster session II at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/.



The poster titled, "ZYN002 Cannabidiol Transdermal Gel: Efficacy and Safety Findings in Children and Adolescents With Autism Spectrum Disorder (ASD) and Related Disorders," shows that Zygel(tm) may provide important clinical promise across a spectrum of endpoints, including, behavior, seizure reduction and sleep. The data are from two open-label Phase 2 trials and one double-blind placebo-controlled trial when added to standard of care in children and adolescents. Three groups of patients were evaluated: patients with autism spectrum disorder (ASD); patients with developmental epileptic encephalopathies (DEE) with comorbid ASD; and patients with fragile X syndrome (FXS) with comorbid ASD.

"The previously disclosed data from these three studies provide evidence of the potential for Zygel to have a clinically meaningful impact on a variety of endpoints associated with ASD and related disorders," said Joseph M. Palumbo, M.D., LFAPA, MACPsych, Chief Medical Officer of Zynerba. "Should these findings be confirmed in additional trials, we believe Zygel has the potential of being a new and differentiated therapeutic option for these patient communities."